Healthcare

September 19, 2017

7 Million Moroccans Suffer from Obesity: UN Report

Seven million Moroccans, or an astonishing 20.6 percent of the population, were suffering from obesity as of 2014, a 5.4 percent increase compared to 2005, according to UN State of Food Security and Nutrition in their World 2017 report.

"...

September 18, 2017

IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’

(AETOS Wire)-- IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost."...

September 18, 2017

CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics

The CHMP of the EMA has issued a positive opinion for an update of the Summary of Product Characteristics (SmPC) for Pradaxa® (dabigatran etexilate)

The CHMP recommends to include data showing that catheter ablation can be conducted in patients on 150 mg twice daily Pradaxa®, without interrupting Pradaxa® treatment

September 17, 2017

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®

(AETOS Wire) -- Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three observational, non-interventional, direct-to-patient studies designed to collect real world data on the use of the EXOGEN Ultrasound Bone Healing System. EXOGEN uses safe, effective low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process. The BONES studies will compare the incidence of fracture nonunions in patients utilizing EXOGEN with patients from a national......

September 15, 2017

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cyltezo® (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases
Recommendation based on extensive analytical, pharmacological, non –clinical & clinical data, which demonstrated...

September 15, 2017

Global Foundation Launches to Accelerate an End to Smoking

Foundation for a Smoke-Free World Secures Major 12 Year Funding Commitment; Shares Initial Plans to Reduce Harm and Deaths from Smoking Worldwide (AETOS Wire)-- With the goal of eliminating smoking worldwide, the Foundation for a Smoke-Free World formally launched today in New York City. The Foundation is founded and led by Dr. Derek Yach, a renowned anti-smoking crusader who, while at the World Health Organization (WHO), was the primary architect of the WHO’s Framework Convention on Tobacco Control. The Foundation will build upon......

September 15, 2017

Two New Innovative Swiss Made EDOF IOLs for Cataract Surgery

(AETOS Wire)-- The company Swiss Advanced Vision (SAV-IOL SA) announced today the launch of LUCIDIS and EDEN, two new intraocular lenses (IOLs) for the cataract surgery, both using the Instant Focus EDOF patented technology. With a brand-new concept,"...

September 13, 2017

Life Line Screening Expands Product Base to DNA, Clinical Trials

(AETOS Wire)-- Life Line Screening, a leader in community-based preventive healthcare, is deepening its delivery model of face-to-face patient care to provide access to advanced precision medicine through DNA testing and clinical trials.

This"...

September 13, 2017

Kaneka Eurogentec Announces the Construction of a New Large Scale Pharmaceutical Grade Biologics Manufacturing Facility

(AETOS Wire)-- Kaneka Eurogentec, a custom service and FDA inspected contract development and manufacturing organization (CDMO), announced today that its board has approved the construction of a new state of-the-art GMP facility adjacent to its current"...

September 12, 2017

Jardiance® reduced risk of cardiovascular death in people with type 2 diabetes and established CV disease* independent of background blood sugar control

Three sub-analyses of the EMPA-REG OUTCOME® trial in people with type 2 diabetes and established cardiovascular disease* presented at EASD 20171-3
Irrespective of their blood sugar control at study start, participants* taking Jardiance® had a lower risk of cardiovascular death compared to placebo1
Jardiance® also reduced...